STOCK TITAN

Chromocell Therapeutics Corporation - $CHRO STOCK NEWS

Welcome to our dedicated page for Chromocell Therapeutics Corporation news (Ticker: $CHRO), a resource for investors and traders seeking the latest updates and insights on Chromocell Therapeutics Corporation stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Chromocell Therapeutics Corporation's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Chromocell Therapeutics Corporation's position in the market.

Rhea-AI Summary
Chromocell Therapeutics (CHRO) announces successful IPO, raising $6.6 million and outlining development plans for non-opioid pain treatments. Key highlights include debt conversions, CEO compensation deferral, and pipeline progress targeting NaV1.7 sodium channel.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.37%
Tags
none
-
Rhea-AI Summary
Chromocell Therapeutics Corp. launches an eye pain treatment program targeting a $2.5 billion market opportunity. The program focuses on sodium channel NaV1.7 for various acute and chronic eye pain indications. Dr. Simon Chandler, with extensive experience in ophthalmic drug development, leads the program to provide effective treatment options for sufferers globally.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.8%
Tags
none
-
Rhea-AI Summary
Chromocell Therapeutics Corp. appoints Frank Knuettel as permanent CEO, expressing confidence in his leadership to advance non-opioid pain treatment therapies.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.44%
Tags
none
Rhea-AI Summary
Chromocell Therapeutics Corp. announced CEO Frank Knuettel will present at the Sidoti March Virtual Investor Conference to discuss non-opioid pain treatment therapeutics. Investors can access the presentation live on March 13-14, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.31%
Tags
conferences
-
Rhea-AI Summary
Benuvia Operations, LLC and Chromocell Therapeutics Corp. announce a Development and License Agreement for non-opioid pain treatment therapies. The agreement includes licensing of sublingual formulations for acute pain, intranasal spray formulation, and sublingual spray formulation for related conditions, aiming to enhance patient outcomes and address medical needs. Chromocell plans to develop clinical programs for the licensed products within 18 months, supported by Benuvia's manufacturing and supply services. This strategic alliance emphasizes both companies' dedication to advancing healthcare through innovative research and development.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.76%
Tags
partnership
-
Rhea-AI Summary
Chromocell Therapeutics Corporation (CHRO) successfully closes its initial public offering, raising approximately $6.6 million. The company offered 1,100,000 shares of common stock at $6.00 per share. A.G.P./Alliance Global Partners acted as the book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.42%
Tags
Rhea-AI Summary
Chromocell Therapeutics Corporation (CHRO) announced the pricing of its IPO, raising $6.6 million. The company plans to list on NYSE American under the symbol CHRO. Funds will be used for clinical studies, market strategy, and repaying promissory notes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Chromocell Therapeutics Corporation

NYSE:CHRO

CHRO Rankings

CHRO Stock Data

10.80M
5.88M
United States of America